Medical Compression Systems Release: FDA Approves the Next Generation ActiveCare
FDA Approves the Next Generation ActiveCare
Innovative Platform Combines Unique Post-Op Patient Monitoring App with Proven Mobile Compression Therapy Device
CONCORD, Massachusetts, August 8, 2016 /PRNewswire/ --
Medical Compression Systems (MCS), announced today that it has obtained US Food and Drug Administration (FDA) clearance for its new comprehensive monitoring application, in combination with ActiveCare®, a device previously proven to provide safe and effective Deep Vein Thrombosis (DVT) prevention, improved patient's satisfaction and significant hospital cost reduction for Total Joint patients.
The ActiveCare® Online platform is equipped with Bluetooth, enabling wireless data transmission between patients and their healthcare providers.
This FDA clearance provides hospitals and caregivers with a state-of-the-art approach to achieve better results in accordance with CMS's new bundled payment Comprehensive Care for Joint Replacement (CJR) program, which financially rewards institutions that improve their overall patient outcomes.
According to Gerry Feldman, MCS CEO and Vice Chairman of the Board: "This news provides an immediate opportunity to improve post-surgical outcomes and patient satisfaction following surgery, by monitoring and improving patient compliance with therapy. Better outcomes -reducing complications and readmissions - are expected to result in substantial cost savings to institutions, all of which can help hospitals to excel in the CJR program. ActiveCare® Online will allow hospitals to better communicate with and monitor patients during CMS's required post discharge 90-day period."
The new ActiveCare® Online system is a pioneering, portable, lightweight device that accompanies the patient from the hospital throughout rehabilitation to home. ActiveCare® Online uses Synchronized Flow Technology (S.F.T) for effective and safe DVT prevention during and after surgery. The device is equipped with Bluetooth, enabling wireless transmission via an application that is installed on the patient's smartphone to record their daily health status, compliance and activity level. The secure Data Output from the device can be reviewed by authorized medical staff. ActiveCare® Online also includes a 24-hour patient support hotline.
About ActiveCare®
ActiveCare® is a brand of MCS, a leader in wearable, non-invasive smart compression therapy devices that enhance arterial, venous and lymphatic circulation and create new clinical and economic value compared to available alternatives. MCS is the first and only company to offer the healthcare market a new class of therapy which combines MCS's patented Synchronized Flow Technology (ActiveCare® + S.F.T.) device, proven to effectively prevent DVT with no risk of bleeding complications, thus improving the healthcare standard. ActiveCare® fully meets the American College of Chest Physicians' Evidence-Based Clinical Practice Guidelines (ACCP 2012) to prevent DVT after total joint replacement for the duration of treatment, from hospital to home.
About MCS Medical Compression Systems
Founded in 1997, MCS Medical Compression Systems (Ltd.) is an Israeli publicly traded company on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc., the company's subsidiary, is located in the USA. For more information, please visit http://www.activecare.mcsmed.com.
Media Contact:
Mrs. Tlalit Bussi Tel Tzure - VP Marketing
MCS - Medical Compression System
Tlalit@mcsmed.com
Innovative Platform Combines Unique Post-Op Patient Monitoring App with Proven Mobile Compression Therapy Device
CONCORD, Massachusetts, August 8, 2016 /PRNewswire/ --
Medical Compression Systems (MCS), announced today that it has obtained US Food and Drug Administration (FDA) clearance for its new comprehensive monitoring application, in combination with ActiveCare®, a device previously proven to provide safe and effective Deep Vein Thrombosis (DVT) prevention, improved patient's satisfaction and significant hospital cost reduction for Total Joint patients.
The ActiveCare® Online platform is equipped with Bluetooth, enabling wireless data transmission between patients and their healthcare providers.
This FDA clearance provides hospitals and caregivers with a state-of-the-art approach to achieve better results in accordance with CMS's new bundled payment Comprehensive Care for Joint Replacement (CJR) program, which financially rewards institutions that improve their overall patient outcomes.
According to Gerry Feldman, MCS CEO and Vice Chairman of the Board: "This news provides an immediate opportunity to improve post-surgical outcomes and patient satisfaction following surgery, by monitoring and improving patient compliance with therapy. Better outcomes -reducing complications and readmissions - are expected to result in substantial cost savings to institutions, all of which can help hospitals to excel in the CJR program. ActiveCare® Online will allow hospitals to better communicate with and monitor patients during CMS's required post discharge 90-day period."
The new ActiveCare® Online system is a pioneering, portable, lightweight device that accompanies the patient from the hospital throughout rehabilitation to home. ActiveCare® Online uses Synchronized Flow Technology (S.F.T) for effective and safe DVT prevention during and after surgery. The device is equipped with Bluetooth, enabling wireless transmission via an application that is installed on the patient's smartphone to record their daily health status, compliance and activity level. The secure Data Output from the device can be reviewed by authorized medical staff. ActiveCare® Online also includes a 24-hour patient support hotline.
About ActiveCare®
ActiveCare® is a brand of MCS, a leader in wearable, non-invasive smart compression therapy devices that enhance arterial, venous and lymphatic circulation and create new clinical and economic value compared to available alternatives. MCS is the first and only company to offer the healthcare market a new class of therapy which combines MCS's patented Synchronized Flow Technology (ActiveCare® + S.F.T.) device, proven to effectively prevent DVT with no risk of bleeding complications, thus improving the healthcare standard. ActiveCare® fully meets the American College of Chest Physicians' Evidence-Based Clinical Practice Guidelines (ACCP 2012) to prevent DVT after total joint replacement for the duration of treatment, from hospital to home.
About MCS Medical Compression Systems
Founded in 1997, MCS Medical Compression Systems (Ltd.) is an Israeli publicly traded company on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc., the company's subsidiary, is located in the USA. For more information, please visit http://www.activecare.mcsmed.com.
Media Contact:
Mrs. Tlalit Bussi Tel Tzure - VP Marketing
MCS - Medical Compression System
Tlalit@mcsmed.com